This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Aloxi

Eisai Co., Ltd.

Drug Names(s): palonosetron hydrochloride, E3270, Onicit, Paloxi

Description: Aloxi (palonosetron hydrochloride) is an antiemetic and antinauseant agent. It is a selective serotonin subtype 3 (5-HT3) receptor antagonist with a strong binding affinity forthis receptor and little or no affinity for other receptors.

Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema. It is thought that chemotherapeutic agents produce nausea and vomiting by releasing serotonin from the enterochromaffin cells of the small intestine and that the released serotonin then activates 5-HT3 receptors located on vagal afferents to initiate the vomiting reflex.

Deal Structure: Aloxi was originally developed by Syntex.

Syntex and Roche
In May 1994, Syntex agreed to be acquired by Roche Holdings. Roche will pay $24 a share in cash for Syntex stock for a total of $5.3 billion.

MGI Pharma (Eisai) and Helsinn
In February 2001, MGI Pharma and Helsinn signed a letter of intent for exclusive North American license and distribution rights to Aloxi. Under terms of the letter of intent, MGI made a $5 million deposit to Helsinn. MGI will make additional payments upon concluding the license agreement and based on the achievement of certain milestones leading up to the approval of palonosetron in the U.S. Helsinn will continue to fund and conduct all development of palonosetron. MGI will also pay royalties and product supply fees based upon net sales. Helsinn will supply finished product ready for distribution.

In December 2007, Eisai and MGI Pharma announced that they entered into a definitive merger agreement under which...See full deal structure in Biomedtracker

Partners: Helsinn Healthcare SA Swedish Orphan Biovitrum Otsuka Holdings Co., Ltd. Mundipharma International Limited Roche Holding AG Chugai Pharmaceutical Co., Ltd. The Galenica Group


Aloxi News

Pink Sheet Aloxi FDA Reviewers


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug